1. Medtech Insight
  2. >>Archive

Major Players Keep Remote Patient Monitoring Moving Forward

Medtronic and Roche have made important moves in the remote monitoring market with new partnerships designed to enhance their places in telemedicine, which continues to be an important point of emphasis for providers. Meanwhile, AliveCor, a young company with groundbreaking cardiology technology for the smartphone, has reached an important milestone in Europe.

The remote monitoring market continues to advance, and interest in the field is being marked by deals and collaborations involving players hoping to stay in front of the trend. (SeeAlso see "Digital Health Pushing Telemedicine To Center Stage" - Medtech Insight, 30 October, 2014..) One of the newest partnerships involves Cardiocom LLC, the patient monitoring services business owned by Medtronic PLC. The new deal is with LHC Group, which provides home health, hospice, and comprehensive post-acute health care services in the US, and the agreement adds to the growing number of home health agencies signing up to work with Cardiocom. Medtronic says it now has deals with four of the five largest agencies in the US.

The agreement calls for Medtronic to provide telehealth devices to LHC’s transitions program, which utilizes a disease management approach to help reduce emergency room visits as well as prevent avoidable readmissions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.